scispace - formally typeset
N

Neta Erez

Researcher at Tel Aviv University

Publications -  73
Citations -  5119

Neta Erez is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Metastasis & Tumor microenvironment. The author has an hindex of 29, co-authored 59 publications receiving 3922 citations. Previous affiliations of Neta Erez include Weizmann Institute of Science & University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

TL;DR: It is shown that normal dermal fibroblasts can be "educated" by carcinoma cells to express proinflammatory genes, and this ability to "educate" them is shown to be related to tumor-enhancing inflammation.
Journal ArticleDOI

The Dark Side of Fibroblasts: Cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment

TL;DR: Recent advancements in understanding of how CAFs drive the recruitment and functional fate of tumor-infiltrating immune cells toward an immunosuppressive microenvironment are focused on, and outlook on future therapeutic implications are provided.
Journal ArticleDOI

Plasticity in Tumor-Promoting Inflammation: Impairment of Macrophage Recruitment Evokes a Compensatory Neutrophil Response

TL;DR: A mechanism whereby CCL2 attracts proangiogenic CCR2(+) macrophages with the ancillary capability to limit infiltration by neutrophils is suggested, providing alternative paracrine support for tumor angiogenesis and progression.
Journal ArticleDOI

Activated p53 suppresses the histone methyltransferase EZH2 gene

TL;DR: It is suggested that the p 53-dependent suppression of EZH2 expression is a novel pathway that contributes to p53-mediated G2/M arrest and may lead to novel approaches to control cancer progression.
Journal ArticleDOI

Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1

TL;DR: It is suggested that targeting Chi3L1 may be clinically beneficial in breast cancer, and a novel signaling axis between fibroblasts, cancer cells and immune cells in breast tumors that drives an immunosuppressive microenvironment, mediated by CAF-derived Chi3 L1 is reported.